Historically, prostate biopsy was performed because of a prostate-specific antigen (PSA)
level exceeding a specific threshold or suspicious findings on digital rectal examination …

Prostate cancer is the most commonly diagnosed cancer in men. At present, patients are
selected for prostate biopsy on the basis of age, serum prostate specific antigen (PSA), and …

Prostate cancer (PCa) screening has been substantially influenced by the clinical
implementation of serum prostate-specific antigen (PSA). In this context, improvement of …

Introduction Many new markers are now available as an aid for decisions about prostate
biopsy for men without prostate cancer and/or to improve risk stratification for men with …

OBJECTIVES To develop a logistic regression‐based model to predict prostate cancer
biopsy at, and compare its performance to the risk calculator developed by the Prostate …

Purpose: We performed a cost-effectiveness analysis using the PHI (Prostate Health Index),
4Kscore®, SelectMDx™ and the EPI (ExoDx™ Prostate [IntelliScore]) in men with elevated …

Background: Determining the need for prostate biopsy is frequently difficult and more
objective criteria are needed to predict the presence of high grade prostate cancer (PCa). To …

Objectives Selecting patients suspected of having prostate cancer (PCa) for a prostate
biopsy remains a challenge. Prostate‐specific antigen (PSA)‐based testing is hampered by …

Millions of men each year are faced with a clinical suspicion of prostate cancer (PCa) but the
prostate biopsy fails to detect the disease. For the urologists, how to select the appropriate …

Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer
appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically …